|
1）永井良三．慢性炎症研究の歴史．実験医学．2011; 29: 1508-17
|
|
|
|
2）Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010; 10: 826-37
|
|
|
|
|
3）高橋将文．インフラマソームを介した無菌性炎症と心血管病．実験医学．2012; 30: 1750-5
|
|
|
|
|
|
4）Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340: 115-26
|
|
|
|
|
5）Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol. 2011; 29: 707-35
|
|
|
|
|
|
6）Feldmann J, Prieur AM, Quartier P, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet. 2002; 71: 198-203
|
|
|
|
|
|
7）Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002; 10: 417-26
|
|
|
|
|
|
8）Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440: 237-41
|
|
|
|
|
|
9）Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006; 86: 515-81
|
|
|
|
|
|
10）Kirii H, Niwa T, Yamada Y, et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003; 23: 656-60
|
|
|
|
|
|
11）Isoda K, Sawada S, Ishigami N, et al. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2004; 24: 1068-73
|
|
|
|
|
|
12）Devlin CM, Kuriakose G, Hirsch E, et al. Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc Natl Acad Sci U S A. 2002; 99: 6280-5
|
|
|
|
|
|
13）Yajima N, Takahashi M, Morimoto H, et al. Critical role of bone marrow apoptosis-associated speck-like protein, an inflammasome adaptor molecule, in neointimal formation after vascular injury in mice. Circulation. 2008; 117: 3079-87
|
|
|
|
|
|
14）Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010; 464: 1357-61
|
|
|
|
|
|
15）Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010; 11: 155-61
|
|
|
|
|
|
16）Rajamaki K, Lappalainen J, Oorni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One. 2010; 5: e11765
|
|
|
|
|
|
17）Menu P, Pellegrin M, Aubert JF, et al. Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome. Cell Death Dis. 2011; 2: e137
|
|
|
|
|
|
18）Usui F, Shirasuna K, Kimura H, et al. Critical role of caspase-1 in vascular inflammation and development of atherosclerosis in western diet-fed apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 2012; 425: 162-8
|
|
|
|
|
|
19）Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007; 356: 1517-26
|
|
|
|
|